Remedy Plan, Inc.

Gaithersburg, MD · Biotech · Private

Hyperbolic inhibitor drug candidate (RPT1G) targeting NAMPT enzyme for cancer and multi-disease treatment

Claim this profile

Follows are private to you and power your alerts

Updated · remedyplan.com

Sector
Biotech
Headquarters
Gaithersburg, MD
Latest Form D
$19.1M, Aug 2023
Total capital
$25.8M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$25.8M
3 Form D · last Aug 2023
39 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
2
9 pending · first 2026
Rank in peer group#397 of 1449

Capital timeline

201820192020202120222023FEDERAL ↑EQUITY ↓Cumulative $25.8M1st Form D$1.5M2nd Form D$5.2M3rd Form D$19.1M
201820192020202120222023FEDERAL ↑EQUITY ↓Cumulative $25.8M2nd Form D$5.2M3rd Form D$19.1M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$19.1M
  • Private capital raisedForm D · SEC · 2nd filing$5.2M
  • Private capital raisedForm D · SEC · 1st filing$1.5M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#397 · top 27%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Alexandra ManickDirectorNamed in SEC Form D filings
  • Frank McCormickDirectorNamed in SEC Form D filings
  • Gregory Plan CrimminsExecutive Officer, DirectorNamed in SEC Form D filings
  • Owen HughesDirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 11
Show all 11 patent records
  • Cancer Treatments Targeting Cancer Stem CellsMay 7, 2026 · Application 19380103Pending
  • Cancer Treatments Targeting Cancer Stem CellsApr 28, 2026 · US 12,612,368Granted
  • Cancer Treatments Targeting Cancer Stem CellsJan 13, 2026 · US 12,522,587Granted
  • Nampt Inhibitors And Uses ThereofNov 14, 2024 · Application 18560228Pending
  • Cancer Treatments Targeting Cancer Stem CellsApplication 62931531Pending
  • Cancer Treatments Targeting Cancer Stem CellsApplication PCTUS2019030664Pending
  • Cancer Treatments Targeting Cancer Stem CellsApplication 62815251Pending
  • Cancer Treatments Targeting Cancer Stem CellsApplication 62667412Pending
  • Nampt Inhbitors And Uses ThereofApplication PCTUS2022029259Pending
  • Nampt Inhibitors And Uses ThereofApplication 63188399Pending
  • Cancer Treatments Targeting Cancer Stem CellsApplication PCTUS2020059329Pending
  • BIOMORPH TECHNOLOGIES LLCSimilar federal contract value in Biotech · null in contracts
  • KisoTerra Biotech Corp.Similar federal contract value in Biotech · null in contracts
  • 858 TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Vyome Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
  • Pliant.io, Inc.Similar federal contract value in Biotech · null in contracts
  • INNOVAGYN, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .